PharmaEssentia revenue and financials
$1,190.00Change from previous close: +2.15%Absolute change: +$25.00
In the fiscal year ended December 2025, PharmaEssentia reported revenue of $15.63B (+60.61% year over year). Net income was $5.05B, a net margin of 32.3%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +60.61%
- 2025 vs 2024
- Net income growth
- +70.13%
- 2025 vs 2024
- Net margin
- 32.3%
- 2024: 30.5%
Financial data
Amounts in millions of TWD; per-share values in TWD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | 15,635 | 9,735 | 5,106 | 2,882 |
| Cost of revenue | 1,684 | 1,177 | 611 | 812 |
| Gross profit | 13,950 | 8,558 | 4,495 | 2,070 |
| Selling, general and administrative | 5,554 | 4,234 | 4,184 | 2,672 |
| Research and development | 3,468 | 2,588 | 2,224 | 1,426 |
| Operating income | 4,928 | 1,736 | -1,913 | -2,028 |
| EBIT | 5,008 | 3,017 | -940 | -1,823 |
| EBITDA | 5,407 | 3,385 | -671 | -1,595 |
| Interest expense | 25.5 | 22.2 | 46.7 | 18.5 |
| Pre-tax income | 4,983 | 2,995 | -987 | -1,842 |
| Income tax | -62.2 | 29.1 | -363 | -467 |
| Net income | 5,045 | 2,966 | -624 | -1,375 |
| Net income to common shareholders | 5,045 | 2,966 | -624 | -1,375 |
| Basic EPS | 12.30 | 7.27 | -1.57 | -3.93 |
| Diluted EPS | 12.25 | 7.21 | -1.57 | -3.93 |
| Average shares (basic) | 410 | 408 | 397 | 350 |
| Average shares (diluted) | 412 | 411 | 397 | 350 |